Vincent J. Van Der Velden

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 152 publications

Increased Mast Cell Numbers in Bone Marrow of Patients with Myeloproliferative Neoplasms (MPN) and Pruritus.

Increased Mast Cell Numbers in Bone Marrow of Patients with Myeloproliferative Neoplasms (MPN) and Pruritus.

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: June 26, 2026

Increased Mast Cell Numbers in Bone Marrow of Patients with Myeloproliferative Neoplasms and Pruritus

Increased Mast Cell Numbers in Bone Marrow of Patients with Myeloproliferative Neoplasms and Pruritus

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: June 26, 2026

Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients.

Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients.

Journal: Blood cancer journal

Published: March 23, 2026

Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial.

Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Haematology

Published: January 27, 2026

Generation of Functionally Competent Human Mast Cells from Limited Blood Volumes.

Generation of Functionally Competent Human Mast Cells from Limited Blood Volumes.

Journal: International journal of molecular sciences

Published: December 22, 2025

Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study.

Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study.

Journal: HemaSphere

Published: July 18, 2025

Immunotherapy for rapid bone marrow conditioning and leukemia depletion that allows efficient hematopoietic stem cell transplantation.

Immunotherapy for rapid bone marrow conditioning and leukemia depletion that allows efficient hematopoietic stem cell transplantation.

Journal: Journal for immunotherapy of cancer

Published: June 16, 2025

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.

Journal: Blood

Published: June 03, 2025

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.

Journal: Blood

Published: May 29, 2025

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.

Journal: Blood

Published: May 29, 2025

Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.

Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.

Journal: Leukemia

Published: May 28, 2025

CompensAID: An Automated Detection Tool for Reference Errors.

CompensAID: An Automated Detection Tool for Reference Errors.

Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology

Published: April 30, 2025

Showing 1-12 of 152

Last Updated: 09/26/2026